📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
386 announcements match the current filters (relevance ≥ 5).
Parag Milk Foods FY26 PAT Up 19% to ₹141 Cr; New Age Business Revenue Grows 91%
Parag Milk Foods reported a resilient FY26 with revenue growing 11% to ₹3,818 crore and PAT (before exceptional items) rising 19% to ₹141 crore. The company successfully navigated a 16% YoY increase in raw milk prices by improving its product mix and implementing calibrated price hikes, leading to a Q4 gross margin of 28%. A standout performer was the 'New Age Business' (Avvatar and Pride of Cows), which grew 91% during the year and now contributes 10% to total turnover. While Q4 saw a 5% volume decline, core categories like Ghee and Cheese maintained strong market shares of 22% and 35% respectively.
Key Highlights
FY26 Revenue reached ₹3,818 Cr (+11% YoY) with PAT (before exceptional items) at ₹141 Cr (+19% YoY).
New Age Business (Avvatar & Pride of Cows) grew 91% in FY26, crossing the ₹100 Cr quarterly revenue milestone in Q4.
Gross Profit Margin improved to 28.0% in Q4 FY26 from 26.7% YoY, despite 15% YoY milk price inflation.
Core categories (Ghee, Cheese, Paneer) witnessed 16% value growth; Gowardhan Ghee maintains 22% market share.
Q4 FY26 PAT grew 23% YoY to ₹32 Cr, supported by premiumization despite a 5% overall volume decline.
👀 What to Watch
Investors should focus on the company's successful transition toward high-margin value-added products like Avvatar whey protein, which is effectively cushioning the impact of milk price volatility. The stock remains a play on the premiumization of the Indian dairy sector and improved margin profiles from the New Age segment.
Parag Milk Foods FY26 Revenue at ₹3,742 Cr; Recommends ₹1.10 Dividend and Allots 10L ESOP Shares
Parag Milk Foods reported a total revenue of ₹3,742.03 crores for FY26, with Q4 revenue standing at ₹946.17 crores. The Board recommended a final dividend of ₹1.10 per share (11% of face value) for the fiscal year, subject to shareholder approval. To support employee incentives, 1,000,000 equity shares were allotted to the ESOP Trust, increasing the total paid-up capital to ₹126.11 crores. The company also moved a promoter group entity with zero holding to the public category, streamlining its shareholding structure.
Key Highlights
Annual revenue from operations reached ₹3,742.03 crores for the financial year ended March 31, 2026.
Board recommended a final dividend of ₹1.10 per equity share (11% of face value).
Allotment of 10,00,000 equity shares to the ESOP Trust under the 2022 scheme.
Q4 FY26 standalone profit after tax recorded at ₹28.28 crores on revenue of ₹946.17 crores.
Total paid-up equity share capital increased to ₹126,10,95,540 following the ESOP allotment.
👀 What to Watch
The steady revenue growth and dividend recommendation are positive indicators for shareholders; investors should monitor the impact of ESOP dilution on future EPS and track margin performance.
Parag Milk Foods Credit Rating Upgraded to IND BBB+; Outlook Stable
India Ratings and Research has upgraded Parag Milk Foods' credit rating for bank facilities and Non-Convertible Debentures (NCDs) to 'IND BBB+' from 'IND BBB'. The short-term rating has also seen an upgrade to 'IND A2' from 'IND A3+', indicating improved liquidity and creditworthiness. The rating action covers bank facilities worth INR 6,000 million and NCDs worth INR 810 million. This upgrade suggests a strengthening financial profile and potentially lower future borrowing costs for the dairy major.
Key Highlights
Long-term rating for INR 6,000 million bank loan facilities upgraded to IND BBB+/Stable.
NCD rating for INR 810 million (reduced from INR 1,050 million) upgraded to IND BBB+.
Short-term bank loan rating upgraded from IND A3+ to IND A2.
Issuer rating upgraded to IND BBB+/Stable prior to its withdrawal at the company's request.
👀 What to Watch
The upgrade is a positive indicator of the company's debt-servicing capability and financial health. Investors should monitor the impact on interest costs and overall profitability in the next few quarters.
BIL Vyapar Cites CIRP for Non-Applicability of Corporate Governance Reporting for Q4 FY26
BIL Vyapar Limited (formerly Binani Industries Limited) has informed stock exchanges that Regulation 27 regarding Corporate Governance reporting is not applicable for the quarter and year ended March 31, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP), which commenced on January 13, 2026. Ms. Rachana Jhunjhunwala has been appointed as the Resolution Professional to oversee the company's affairs. Under SEBI Regulation 15, companies under CIRP are exempt from specific governance compliance filings.
Key Highlights
Company entered Corporate Insolvency Resolution Process (CIRP) effective January 13, 2026.
Ms. Rachana Jhunjhunwala appointed as the Resolution Professional for the insolvency proceedings.
Exemption from Regulation 27 (Corporate Governance) claimed for the fourth quarter and full year ended March 31, 2026.
The filing follows SEBI (LODR) Regulation 15 which provides relief to companies under insolvency.
👀 What to Watch
Investors should exercise extreme caution as the company is in insolvency proceedings, which often results in significant equity dilution or delisting. Monitor the progress of the resolution plan for any updates on potential recovery value for shareholders.
BIL Vyapar CoC Discusses Resolution Plan Extension and Valuation in 8th Meeting
BIL Vyapar Limited, currently under the Corporate Insolvency Resolution Process (CIRP), held its 8th Committee of Creditors (CoC) meeting on April 30, 2026. The CoC discussed a request from a prospective resolution applicant for an extension of time to submit a resolution plan. The meeting also addressed the appointment of a co-ordinating valuer and the approval of CIRP costs. Furthermore, the committee is seeking a new accountant to prepare accounts for audit as the previous auditor expressed inability to perform the task.
Key Highlights
Prospective resolution applicant has requested an extension of time for the submission of the Resolution Plan.
CoC noted the valuation methodology and approved the appointment of a Co-ordinating Valuer.
Committee of Creditors officially took note of and approved the CIRP costs incurred.
Search for a new accountant initiated to prepare accounts for audit purposes following the withdrawal of the previous auditor.
👀 What to Watch
Equity shareholders should exercise extreme caution as CIRP proceedings often lead to significant capital erosion or delisting. Monitor the outcome of the resolution plan submission and the valuation reports to understand potential recovery values.
SPARC to Sell Priority Review Voucher for US $195 Million
Sun Pharma Advanced Research Company (SPARC) has signed a definitive agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for $195 million. The PRV was originally granted by the US FDA following the approval of Sezaby for neonatal seizures. This transaction provides a significant non-dilutive cash infusion, which the company plans to use to accelerate its clinical pipeline and innovation strategy. The deal is currently subject to customary closing conditions, including US antitrust clearance.
Key Highlights
Monetization of Priority Review Voucher (PRV) for a total value of US $195 million
PRV was earned through the FDA approval of Sezaby for treating neonatal seizures
Proceeds to be utilized for accelerating development of pipeline assets and innovation strategy
Transaction is subject to the Hart-Scott-Rodino (HSR) Antitrust Improvements Act waiting period
Stifel acted as the exclusive financial advisor for this asset sale
👀 What to Watch
This is a major liquidity event that provides SPARC with substantial capital to fund its R&D without equity dilution. Investors should monitor how this cash is deployed across their clinical pipeline to drive long-term value.
Paradeep Phosphates Shareholders Approve MD Re-appointment and New Joint MD
Paradeep Phosphates Limited has successfully passed three special resolutions via postal ballot, ensuring leadership continuity. Shareholders approved the re-appointment of Mr. N Suresh Krishnan as Managing Director with 97.99% votes in favor. The appointment of Mr. K K Rajeev Nambiar as Joint Managing Director and Mr. Marco Philippus Ardeshir Wadia as an Independent Director were also approved. However, significant institutional dissent was observed, particularly regarding the Independent Director appointment where 54.31% of institutional votes were cast against the resolution.
Key Highlights
Re-appointment of Mr. N Suresh Krishnan as Managing Director passed with 97.99% total votes in favor.
Appointment of Mr. K K Rajeev Nambiar as Joint Managing Director approved with 91.11% total votes.
Appointment of Mr. Marco Philippus Ardeshir Wadia as Independent Director passed with 85.29% total votes.
Institutional investors showed significant resistance, with 54.31% of their votes against the Independent Director appointment and 32.82% against the Joint MD.
Total of 81.96 crore votes were polled out of 103.81 crore outstanding shares, representing a 78.95% turnout.
👀 What to Watch
While management continuity is positive, investors should monitor the reasons behind the high institutional dissent regarding the Independent Director and Joint MD appointments for potential governance concerns.
Paras Defence Signs MoU with Complus Systems and JV Micronics for Anechoic Chambers
Paras Defence and Space Technologies has entered into a tripartite Memorandum of Understanding (MoU) with Complus Systems and JV Micronics to target the Anechoic and Semi-Anechoic Chambers market. Paras will act as the consortium leader, overseeing the design, manufacturing, and strategic direction of these specialized testing facilities. The partnership leverages Complus's instrumentation expertise and JV Micronics's RF absorber manufacturing to pursue domestic and international opportunities. This strategic move expands Paras's high-tech infrastructure portfolio in the defense and electronics sectors.
Key Highlights
Paras Defence to lead the consortium for design, development, and installation of Anechoic Chambers.
Partnership includes Complus Systems for instrumentation and JV Micronics for RF absorber manufacturing.
The collaboration targets both Indian and international markets for specialized testing infrastructure.
Paras will specifically manufacture Chambers, Filters, and Engineered Points of Entry.
MoU aims to integrate technical expertise to provide end-to-end solutions in the RF testing domain.
👀 What to Watch
Investors should view this as a positive step towards diversifying the company's high-end engineering portfolio. Monitor for future announcements regarding specific contract wins or order book additions resulting from this consortium.
BIL Vyapar Limited Schedules 8th Committee of Creditors Meeting for April 22, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 8th meeting of its Committee of Creditors (CoC) to be held on April 22, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing restructuring process to address the company's debt obligations. Investors should remain aware that the company's management is currently overseen by a Resolution Professional.
Key Highlights
8th meeting of the Committee of Creditors (CoC) scheduled for April 22, 2026
Company is currently under the Corporate Insolvency Resolution Process (CIRP)
Disclosure made pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR)
👀 What to Watch
Investors should exercise extreme caution as equity value is frequently diluted or eliminated during insolvency proceedings. Monitor the outcome of the CoC meeting for updates on potential resolution plans or liquidation risks.
Parsvnath Completes 20.67-Acre 'Saatvik Green NX' Project in Indore
Parsvnath Developers has announced the successful completion of its 'Saatvik Green NX' project in Indore, covering 20.67 acres (83,670 Sqm). The project, which commenced in April 2024, has received its official Completion Certificate from the Office of Collector, District Indore. It features 473 residential plots categorized into Silver, Gold, and Platinum segments. This completion is part of the company's 'MISSION POSSESSION' strategy, focusing on the execution and delivery of ongoing projects to improve its operational track record.
Key Highlights
Completion of 20.67-acre residential plot project 'Saatvik Green NX' in Indore
Delivery of 473 residential plots across Silver, Gold, and Platinum categories
Project execution completed within a 24-month timeframe from April 2024 to April 2026
Official Completion Certificate received from the Office of Collector, District Indore
👀 What to Watch
This development indicates improved execution capabilities for Parsvnath; investors should monitor if this translates into better cash flow and debt reduction in future earnings reports.
Apeejay Surrendra Park Hotels Signs 2 New Management Agreements in Ayodhya and Ujjain
Apeejay Surrendra Park Hotels Limited (ASPHL) has strategically expanded its footprint in the spiritual tourism sector by signing two new management agreements. The company will develop 'Zone Connect by The Park' properties in Ayodhya (56 rooms) and Ujjain (64 rooms), targeting high-demand pilgrimage circuits. These agreements follow an asset-light management model, which is expected to enhance operational efficiency and brand presence without heavy capital expenditure. This expansion brings the company's diverse portfolio closer to its goal of capturing the growing influx of domestic and international religious tourists.
Key Highlights
Signed two hotel management agreements for Zone Connect by The Park in Ayodhya and Ujjain
Ayodhya property features 56 rooms and is located 4.9 km from Ram Janmabhoomi
Ujjain property features 64 rooms and is located 8 km from Mahakaleshwar Jyotirlinga Temple
Expansion utilizes an asset-light management model to strengthen the existing portfolio of 39 hotels
Properties will include full-service amenities like Café C, swimming pools, and banquet facilities
👀 What to Watch
Investors should look favorably on this expansion into high-growth spiritual tourism hubs via an asset-light model. Monitor the company's ability to maintain occupancy rates and ADRs in these competitive religious circuits as they become operational.
Sai Parenterals Approves INR 11.91 Cr Loan for Australian Subsidiary Expansion
The Board of Sai Parenterals has approved an unsecured loan of up to AUD 1.75 million (approximately INR 11.91 crore) to its wholly-owned subsidiary, Sai Singapore Pte. Ltd. These funds are designated for downstream investment into Noumed Pharmaceuticals PTY Limited, the company's step-down subsidiary in Australia. This move signifies a strategic effort to bolster its international operations and provide financial support to its Australian business unit. The transaction highlights the company's focus on global market penetration through its existing subsidiary network.
Key Highlights
Approved financial assistance via unsecured loan not exceeding AUD 1.75 million or SGD 1.610 million.
Total investment value is approximately INR 11,91,40,000.
Funds to be routed through Sai Singapore Pte. Ltd. to Noumed Pharmaceuticals PTY Limited, Australia.
The board meeting concluded on April 20, 2026, confirming the strategic capital allocation.
👀 What to Watch
Investors should monitor the revenue contribution from the Australian subsidiary in future earnings to evaluate the effectiveness of this capital infusion. The stock remains a positive watch for those tracking the company's international growth trajectory.
Uniparts India Receives Relief as ₹25.8 Crore Tax Demand is Fully Deleted
Uniparts India Limited has successfully resolved a significant tax dispute for the Assessment Year 2024-25. The Assistant Commissioner of Income Tax issued a rectification order that completely deletes a previously outstanding tax demand of INR 25.8 crore. This development removes a substantial potential liability from the company's books, improving financial clarity. The order was received by the company on April 17, 2026, following an earlier assessment order.
Key Highlights
Tax demand of INR 25,79,86,410 (₹25.8 crore) has been fully deleted by tax authorities.
Rectification order issued for Assessment Year 2024-25 under Section 154 of the Income Tax Act.
The order follows a previous assessment update communicated on February 12, 2026.
The deletion of this demand removes a significant legal and financial overhang for the company.
👀 What to Watch
This is a positive development as it eliminates a major contingent liability and protects the company's cash flows. Investors should view this as a reduction in regulatory risk for the stock.
Paras Defence Signs 10-Year Exclusive Agreement with Northstar USA for Air-to-Air Refueling
Paras Defence and Space Technologies has entered into a strategic 10-year exclusive agreement with US-based Bandak Aviation Inc. (Northstar). The collaboration aims to supply and support air-to-air refueling systems and accessories specifically for the Indian Armed Forces. Under this agreement, Paras will develop local facilities and depot-level capabilities to provide maintenance and support services. This partnership positions Paras as a key player in a specialized high-tech aerospace niche within the Indian defense market.
Key Highlights
Signed a 10-year exclusive agreement with Bandak Aviation Inc. DBA Northstar, USA.
Focuses on air-to-air refueling systems, accessories, and associated services for Indian Armed Forces.
Paras will develop specialized facilities and depot-level capabilities for product support in India.
Exclusive nature of the deal ensures Paras is the sole Indian partner for Northstar's specific product line.
Strengthens the company's position in the high-entry-barrier aerospace and defense technology sector.
👀 What to Watch
This is a positive development that enhances Paras's long-term revenue visibility and technical expertise. Investors should monitor for specific contract announcements or order book additions resulting from this partnership.
BIL Vyapar Limited Schedules 7th Committee of Creditors Meeting for April 13, 2026
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced the 7th meeting of its Committee of Creditors (CoC) scheduled for April 13, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in determining the future of the company, including potential resolution plans or liquidation. As the company is under CIRP, the management is currently overseen by a Resolution Professional, and the powers of the Board of Directors remain suspended.
Key Highlights
7th meeting of the Committee of Creditors (CoC) to be held on April 13, 2026
Company is currently under Corporate Insolvency Resolution Process (CIRP)
Disclosure made pursuant to Regulation 30 and Para 16(g) of Part A of Schedule III of SEBI LODR
BIL Vyapar Limited was formerly known as Binani Industries Limited (NSE: BILVYAPAR, BSE: 500059)
👀 What to Watch
Investors should exercise extreme caution as equity shareholders typically face significant value erosion or total loss during insolvency proceedings. Monitor the outcomes of CoC meetings for any updates on resolution plans or liquidation orders.
Binani Industries Clarifies Q2 FY25 Discrepancies; Financials Prepared on Liquidation Basis
Binani Industries has responded to NSE's clarification request regarding its Q2 FY25 financial results, citing auditor errors for subsidiary count discrepancies and technical faults for filing delays. The company's financial position is extremely weak, with accumulated losses of ₹21,682 lakhs and a fully eroded net worth. Liabilities exceed total assets by ₹18,543 lakhs, leading auditors to conclude that the 'going concern' assumption is no longer valid. Consequently, the financial statements have been prepared on a liquidation basis, reflecting severe financial distress.
Key Highlights
Accumulated losses reached ₹21,682 lakhs with liabilities exceeding assets by ₹18,543 lakhs as of September 30, 2024.
Auditors stated the 'going concern' assumption is inappropriate and financials are prepared on a liquidation basis.
Outstanding corporate guarantees and letters of comfort total approximately ₹13,196 lakhs for erstwhile subsidiaries.
Reported a standalone net loss of ₹54 lakhs for Q2 FY25 on zero operating income.
Clarified that one subsidiary was struck off in FY 2023-24, leading to previous reporting errors by auditors.
👀 What to Watch
Investors should exercise extreme caution as the company's net worth is fully eroded and it is being valued on a liquidation basis. The significant contingent liabilities and lack of a clear business plan suggest a very high risk of capital loss.
Park Medi World Launches Panchkula Hospital; Group Bed Capacity to Reach 5,460 by 2028
Park Medi World Limited has officially launched its multi-super specialty hospital in Panchkula, strengthening its footprint in the Tricity region alongside its Mohali expansion. The group currently operates 16 hospitals with 3,960 beds and is North India's second-largest hospital chain. The company is executing an aggressive growth plan to add 1,500 beds through five new hospitals and existing facility expansions. This strategic move aims to reach a total capacity of 5,460 beds by March 2028, focusing on high-margin tertiary and quaternary care services.
Key Highlights
Launched a new multi-super specialty hospital in Panchkula, targeting a combined Tricity capacity of 850 beds.
Currently operates 16 hospitals with a total capacity of 3,960 beds across North India.
Planned addition of 1,500 beds through 5 new hospitals and existing facility expansions.
Projected total bed capacity to reach 5,460 beds by March 2028.
Focus on high-acuity care including oncology, neurosciences, and robotic-assisted procedures.
👀 What to Watch
Investors should monitor the occupancy rates and ramp-up speed of the new Panchkula facility as it will be a key revenue driver. The company's aggressive 38% capacity expansion plan by 2028 signals strong long-term growth potential in the healthcare sector.
Paradeep Phosphates Commissions 300 TPD Sulphuric Acid Plant; Total Capacity Reaches 400 TPD
Paradeep Phosphates has successfully commissioned a new 300 TPD Sulphuric Acid Plant at its Mangalore unit as of March 31, 2026. This expansion increases the company's total sulphuric acid capacity from 100 TPD to 400 TPD, involving a total investment of approximately Rs. 240 Crores. The project, funded through internal accruals and term loans, is designed to reduce dependence on imported raw materials and improve operational margins. Furthermore, the plant will utilize waste heat to generate 1,05,000 tonnes of steam annually, significantly enhancing energy efficiency and reducing carbon emissions.
Key Highlights
Successfully commissioned 300 TPD Sulphuric Acid Plant, increasing total capacity to 400 TPD
Total project investment of approximately Rs. 240 Crores funded via internal accruals and term loans
Expected to generate 1,05,000 tonnes of high-pressure steam annually from process waste heat
Aims to reduce CO2 emissions by 19,000 tonnes per year by replacing fossil fuel-based steam
Enhances captive production to reduce import dependence and ensure raw material security
👀 What to Watch
Investors should view this as a positive development for long-term margin expansion and vertical integration. Monitor the company's upcoming quarterly results for improvements in operating efficiency and cost savings.
EID Parry to Close PSRIPL Refinery; To Provision Rs 655 Crore for Liabilities
EID Parry has decided to shut down the refinery operations of its wholly-owned subsidiary, Parry Sugars Refinery India Private Limited (PSRIPL), effective March 31, 2026, due to structural unviability and accumulated losses of Rs 1,406 crore. To settle the subsidiary's liabilities, EID Parry will infuse up to Rs 610 crore in equity and provide a loan of Rs 130 crore. The company expects to create a provision of approximately Rs 655 crore across FY 2025-26 and FY 2026-27, alongside a Rs 46 crore investment impairment. While this stops future operational losses, the immediate financial impact on the consolidated balance sheet is substantial.
Key Highlights
Closure of 2,000 TPD sugar refinery at Kakinada due to accumulated losses of Rs 1,406 crore as of March 2025.
EID Parry to create a financial provision of ~Rs 655 crore over the next two fiscal years.
Board approved equity infusion of Rs 610 crore and an inter-corporate loan of Rs 130 crore to settle subsidiary debts.
Subsidiary bank borrowings stand at Rs 877 crore, with only Rs 137 crore expected to be settled via asset realization.
Impairment of Rs 46 crore to be recognized on the current carrying value of the investment in PSRIPL.
👀 What to Watch
Investors should expect significant pressure on profitability in FY26 and FY27 due to the Rs 655 crore provisioning. While the move eliminates a loss-making segment, the short-term financial hit and the scale of the write-off are major concerns.
EID Parry to Close PSRIPL Refinery; to Infuse Rs 740 Cr to Settle Liabilities
EID Parry has announced the closure of its wholly-owned subsidiary, Parry Sugars Refinery India Private Limited (PSRIPL), effective March 31, 2026, due to structural unviability and accumulated losses of Rs 1,406 crore. To settle the subsidiary's bank borrowings of Rs 877 crore, EID Parry will infuse up to Rs 610 crore in equity and Rs 130 crore in loans. This move will result in a significant financial hit, with the company expected to create provisions of approximately Rs 655 crore across FY26 and FY27, plus a Rs 46 crore impairment charge.
Key Highlights
Closure of the 2,000 TPD Kakinada sugar refinery which had accumulated losses of Rs 1,406 crore as of March 2025.
Parent company to infuse Rs 740 crore total (Rs 610 Cr equity and Rs 130 Cr loan) to settle outstanding bank debts.
Estimated provisioning of Rs 655 crore to be recognized across FY 2025-26 and FY 2026-27.
Additional impairment of Rs 46 crore on the current carrying value of the investment in PSRIPL.
PSRIPL contributed Rs 4,262.45 crore to consolidated revenue in FY25 but had a negative net worth.
👀 What to Watch
Investors should expect significant pressure on EID Parry's profitability in the short term due to the Rs 655 crore provisioning. While the closure eliminates a loss-making unit, the immediate financial burden and cash outflow are substantial.
